Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Blood (2023) 142 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2023-188013

Published: 2023

Journal Articles

Trials in Progress: A Phase I/II Clinical Trial of Off the Shelf Universal Donor Natural Killer Cells Combined with Chemotherapy for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (KARMA)

Margaret Lamb, Terri L. Guinipero, Dean Anthony Lee

Blood (2023) 142 (Supplement 1): 6893.

https://doi.org/10.1182/blood-2023-190561

Published: 2023

Journal Articles

Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL)

Yaya Chu, Keira Foley, Meijuan Tian, Kayleigh Klose, Jessica Ayala-Cuesta, Dean Anthony Lee, Mario Marcondes, Christian Klein, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 2063.

https://doi.org/10.1182/blood-2023-181996

Published: 2023

Journal Articles

CD38 KO /CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma

Ella C Troy, Yasemin Sezgin, Marcelo De Souza Pereira, Joseph Caporale, Gregory K Behbehani, Justin Lyberger, Dean Anthony Lee, Meisam Naeimi Kararoudi

Blood (2023) 142 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2023-174742

Published: 2023

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 184.

https://doi.org/10.1182/blood-2023-190213

Published: 2023

Journal Articles

Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells

Hanna Duàn, Olli Dufva, Emmi Jokinen, Hanna Lähteenmäki, Jay Klievink, Jonas Bouhlal, Jason Theodoropoulos, Heikki Kuusanmäki, Tanja Ruokoranta, Pauliina Rumm, Dean Anthony Lee, Esa Pitkänen, Tomi P Mäkelä, Kimmo Porkka, Oscar Brück, Satu Mustjoki

Blood (2023) 142 (Supplement 1): 66.

https://doi.org/10.1182/blood-2023-174037

Published: 2023

Journal Articles

High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers

Jonas Bouhlal, Petra Nygren, Emmi Jokinen, Essi Laajala, Aleksandr Ianevski, Diogo Dias, Jay Klievink, Hanna Lähteenmäki, Hanna Duàn, Khalid Saeed, Dean Anthony Lee, Tero Aittokallio, Olli Dufva, Satu Mustjoki

Blood (2023) 142 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2023-174386

Published: 2023

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Blood (2022) 140 (Supplement 1): 1885–1886.

https://doi.org/10.1182/blood-2022-169336

Published: 2022

Journal Articles

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Blood (2022) 140 (Supplement 1): 8343–8344.

https://doi.org/10.1182/blood-2022-167535

Published: 2022

Journal Articles

Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Blood (2021) 138 (Supplement 1): 476.

https://doi.org/10.1182/blood-2021-145620

Published: 2021

Journal Articles

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Blood (2021) 138 (Supplement 1): 553.

https://doi.org/10.1182/blood-2021-152833

Published: 2021

Journal Articles

A Multi-Omics Approach for Evaluating the Impact of Cytokines and Donor Source on NK Cell Expansion

Sarah Schlotter, Evelyn Navarro, Marcelo de Souza Fernandes Pereira, Aarohi Thakkar, Prashant Trikha, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2021-153853

Published: 2021

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, Nidhi Sharma, Alison R. Walker, Sarah A Wall, James S. Blachly, Greg K. Behbehani, Hannah Choe, Aarohi Thakkar, Robin Nakkula, Ella Troy, Nicole Szuminski, Marcos J.G. de Lima, Lynn O'Donnell, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2021-150750

Published: 2021

Journal Articles

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Basem M. William, John C. Reneau, Amanda Campbell, Anna Vilgelm, Michelle Watts, Lynn O'Donnell, Ying Huang, Catherine Chung, Marcos J.G. de Lima, Steven Devine, Sumithira Vasu, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1388.

https://doi.org/10.1182/blood-2021-150543

Published: 2021

Journal Articles

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

Meisam Naeimi Kararoudi, Yuya Nagai, Ezgi Elmas, Marcelo de Souza Fernandes Pereira, Syed Abbas Ali, Philip Hollingsworth Imus, Darren Wethington, Ivan Marques Borrello, Dean Anthony Lee, Gabriel Ghiaur

Blood (2020) 136 (21): 2416–2427.

https://doi.org/10.1182/blood.2020006200

Published: 2020

Includes: Supplemental data

Journal Articles

CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity

Meisam Naeimi Kararoudi, PhD DVM, Shibi Likhite, PhD, Ezgi Elmas, Maura Schwartz, Kinnari Sorathia, Kenta Yamamoto, Nitin Chakravarti, PhD, Branden S Moriarity, PhD, Kathrin Meyer, PhD, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-142494

Published: 2020

Journal Articles

Tgfβ-Imprinting Decrease CD38 Expression and Lead to Metabolic Reprogramming on Primary NK Cell

Marcelo de Souza Fernandes Pereira, PhD, Yasemin Sezgin, MS, Aarohi Thakkar, MS, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-143085

Published: 2020

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, MDMBBS, Bhavana Bhatnagar, DO, James S. Blachly, MD, Nicole Szuminski, BS, Lynn O'Donnell, PhD, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-139170

Published: 2020

Journal Articles

Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Hemalatha G Rangarajan, MD, Marcelo De Souza Pereira, Ruta Brazauskas, PhD, Michael R Verneris, MD, Andrew St. Martin, MS, Stephen R. Spellman, MS, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139891

Published: 2020

Journal Articles

Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

Stefan O. Ciurea, MD, Jolie Schafer, Piyanuch Kongtim, MD, Julianne Chen, Doris Soebbing, Kai Cao, MS, MD, Samer A. Srour, MD MS, Elizabeth J. Shpall, MD, Marina Konopleva, MD PhD, Dean Anthony Lee, MD PhD, Richard E. Champlin, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134858

Published: 2020

NARROW

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Trials in Progress: A Phase I/II Clinical Trial of Off the Shelf Universal Donor Natural Killer Cells Combined with Chemotherapy for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (KARMA)

Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL)

CD38 KO /CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells

High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

A Multi-Omics Approach for Evaluating the Impact of Cytokines and Donor Source on NK Cell Expansion

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity

Tgfβ-Imprinting Decrease CD38 Expression and Lead to Metabolic Reprogramming on Primary NK Cell

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only